Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/103836OX40 ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOF
WO 28.05.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/119515 Applicant SHANGHAI PHARMAEXPLORER CO., LTD. Inventor CHAI, Xiaojuan
Provided are a murine or human-mouse chimeric antibody targeting OX40 and a preparation method therefor, wherein the antibody binds to the OX40 antigen and has an anti-tumor activity and other activities.
2.WO/2020/102895METHODS OF TREATING AN AUTOIMMUNE DISEASE
WO 28.05.2020
Int.Class A61K 38/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
Appl.No PCT/CA2019/051653 Applicant THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Inventor GOMMERMAN, Jennifer
The present disclosure provides methods of treating an autoimmune disease (e.g., multiple sclerosis) or reducing inflammation by administering at least a B-cell activating Factor (BAFF) polypeptide to a subject in need thereof. The effect of BAFF on plasmablast/plasma cells and their role in autoimmune diseases is also disclosed.
3.WO/2020/102935ANTI-IL-25 ANTIBODIES AND USE THEREOF
WO 28.05.2020
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
Appl.No PCT/CN2018/116170 Applicant SUZHOU KANOVA BIOPHARMACEUTICAL CO., LTD. Inventor GUO, Li
The present invention provides anti-IL-25 antibodies that are directed against (human) IL-25, nucleic acids that encode such antibodies, compositions, and in particular pharmaceutical compositions that comprise such antibodies; and uses of such antibodies and compositions.
4.WO/2020/103885ANTI-PD-1 ANTIBODIES AND USES THEREOF
WO 28.05.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/119798 Applicant BEIJING BIOCYTOGEN CO., LTD Inventor YANG, Yi
Provided are anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen -binding fragments, and the uses thereof.
5.WO/2020/106695METHODS OF TREATING CANCER
WO 28.05.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2019/062166 Applicant ARIAGEN, INC. Inventor COLABUONO, Peter
The present disclosure relates to methods of treating cancer in a patient using a combination of an inhibitor of an immune checkpoint protein and an indole compound or its phosphate derivative.
6.WO/2020/102904PCDH1-BINDING AGENTS AND USES THEREOF
WO 28.05.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CA2019/051669 Applicant THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Inventor MOFFAT, Jason
The disclosure is directed to novel PCDH-1-binding agents, and to methods and uses of these binding agents. In one embodiment, the disclosure provides antibody variable regions which specifically bind the EC1 domain of PDCH1. The disclosure is also directed to uses of the novel PCDH1-binding agents for treating or preventing infection with New-World hantavirus.
7.WO/2020/106714METHODS AND COMPOSITIONS FOR REDUCING NUMBERS OR ELIMINATING HIV-INFECTED CELLS
WO 28.05.2020
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/US2019/062207 Applicant THE WISTAR INSTITUTE FOR ANATOMY AND BIOLOGY Inventor ABDEL-MOHSEN, Mohamed
A method of reducing or inhibiting migration of HIV-infected CD4+ T cells to tissues comprises contacting the infected cells with a ligand that prevents or inhibits the interaction between a T cell-surface fucosylated glycan and its glycan-binding protein or with a molecule that metabolically inhibits glycosylation or fucosylation in said cell. In vitro and in vivo methods are described. Also described is a diagnostic method employing labeled ligands that bind a fucosylated glycan and provide a signal detectable by non- invasive imaging.
8.WO/2020/102852THERAPEUTIC DENDRIMER
WO 28.05.2020
Int.Class C07D 491/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
22in which the condensed system contains four or more hetero rings
Appl.No PCT/AU2019/051274 Applicant STARPHARMA PTY LTD Inventor OWEN, David James
Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a residue of a camptothecin active covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimer, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.
9.WO/2020/103531APPLICATION OF URSODEOXYCHOLIC ACID OR MEDICINAL SALT THEREOF IN PREPARING ANTI-TUMOR DRUG AND ANTI-TUMOR DRUG
WO 28.05.2020
Int.Class A61K 31/575
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
575substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Appl.No PCT/CN2019/104831 Applicant ZHEJIANG UNIVERSITY Inventor CAI, Zhijian
An anti-tumor drug comprising ursodeoxycholic acid and a pharmaceutically acceptable salt thereof, and an application thereof in preparing an anti-tumor drug. Ursodeoxycholic acid has an inhibitory effect on a variety of tumor cells by means of reducing the proportion of regulatory T cells in tumor-infiltrating lymphocytes, and may also be used as an adjuvant to improve the therapeutic effect of anti-PD-1 drugs.
10.WO/2020/105621INHIBITOR OF CELLULAR IRON UPTAKE
WO 28.05.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2019/045227 Applicant PERSEUS PROTEOMICS INC. Inventor ZHANG Lilin
The present invention addresses the problem of providing an inhibitor of cellular iron uptake targeting TfR, and an inhibitor of binding between human Tf and human TfR. According to the present invention, provided is an inhibitor of cellular iron uptake, said inhibitor comprising an antibody which recognizes the 629th to 633rd amino acids in human transferrin receptor.